N2VC34 Stock Overview
An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
NovoCure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.34 |
| 52 Week High | US$20.24 |
| 52 Week Low | US$7.87 |
| Beta | 0.73 |
| 1 Month Change | 0% |
| 3 Month Change | -28.15% |
| 1 Year Change | 39.82% |
| 3 Year Change | -69.89% |
| 5 Year Change | n/a |
| Change since IPO | -77.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| N2VC34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | -1.6% |
| 1Y | 39.8% | 3.3% | -1.6% |
Return vs Industry: N2VC34 exceeded the BR Medical Equipment industry which returned 3.3% over the past year.
Return vs Market: N2VC34 exceeded the BR Market which returned -1.6% over the past year.
Price Volatility
| N2VC34 volatility | |
|---|---|
| N2VC34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 9.9% |
| 10% least volatile stocks in BR Market | 2.7% |
Stable Share Price: N2VC34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine N2VC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,488 | Ashley Cordova | www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
| N2VC34 fundamental statistics | |
|---|---|
| Market cap | R$10.66b |
| Earnings (TTM) | -R$943.17m |
| Revenue (TTM) | R$3.57b |
3.0x
P/S Ratio-11.3x
P/E RatioIs N2VC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N2VC34 income statement (TTM) | |
|---|---|
| Revenue | US$621.71m |
| Cost of Revenue | US$141.01m |
| Gross Profit | US$480.70m |
| Other Expenses | US$644.89m |
| Earnings | -US$164.19m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 77.32% |
| Net Profit Margin | -26.41% |
| Debt/Equity Ratio | 181.4% |
How did N2VC34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 14:19 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NovoCure Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael King | Citizens JMP Securities, LLC |
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |